Company Encyclopedia
View More
name
Indivior
INDV.US
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal.
4.359 T
INDV.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking51/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-39.57%E
    • Profit Margin6.27%B
    • Gross Margin85.35%A
  • Growth ScoreC
    • Revenue YoY-0.17%D
    • Net Profit YoY85.00%A
    • Total Assets YoY-3.28%D
    • Net Assets YoY-23.95%E
  • Cash ScoreC
    • Cash Flow Margin1594.59%B
    • OCF YoY-0.17%D
  • Operating ScoreB
    • Turnover0.82B
  • Debt ScoreE
    • Gearing Ratio114.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Indivior PLC Proposes Re-Domiciliation to Delaware

    Indivior PLC announced plans to re-domicile from the U.K. to Delaware, U.S., establishing Indivior Pharmaceuticals, Inc. as the new holding company. This move aims to enhance U.S. capital market presence and simplify governance. Shareholders will vote on this proposal on December 11, 2025. If approved, Indivior Pharmaceuticals shares will replace Indivior shares on Nasdaq, aligning with the U.S.-based majority shareholder base.

    TradingView·
    UK
    INDV
    0.00%
    TradingView·
    UK
    INDV
    0.00%

    Indivior (INDV) Is Up 25.9% After Strong Q3 Results and Raised Revenue Guidance Has The Bull Case Changed?

    Indivior PLC's shares surged 25.9% following strong Q3 results, with net income doubling to $42 million and sales reaching $314 million. The company raised its 2025 revenue guidance to $1.18-$1.22 billion, bolstered by positive real-world evidence for its SUBLOCADE treatment. Despite the optimistic outlook, concerns about competition, market access, and execution risks remain. Fair value estimates for Indivior range from $32.35 to $106.17 per share, reflecting varied investor perspectives on its future potential.

    Simplywall·
    US
    INDV
    +2.21%
    UK
    INDV
    0.00%
    Simplywall·
    US
    INDV
    +2.21%
    UK
    INDV
    0.00%

    Indivior Study Finds Monthly Injectable Buprenorphine Lowers Relapse and Healthcare Use in OUD Patients

    Indivior plc has presented new evidence on the impact of monthly injectable buprenorphine, SUBLOCADE®, for opioid use disorder (OUD) at the AMCP Nexus 2025 conference. The study shows that patients with high adherence to SUBLOCADE had lower relapse rates, reduced healthcare use, and better chronic disease management compared to those with low adherence. However, the study has limitations, including potential bias and the influence of the COVID-19 pandemic.

    Reuters·
    UK
    INDV
    0.00%
    US
    INDV
    +2.21%
    Reuters·
    UK
    INDV
    0.00%
    US
    INDV
    +2.21%

    Laureate Education’s Earnings Call Highlights Robust Growth

    Laureate Education's earnings call highlighted strong third-quarter results, with revenue of $400 million and adjusted EBITDA of $95 million, exceeding prior guidance. Enrollment grew by 7%, and the company expanded its stock repurchase program by $150 million. However, challenges include timing impacts in Peru and sluggish economic conditions in Mexico. The company raised its full-year 2025 guidance, projecting revenue between $1.681 billion and $1.686 billion. Despite challenges, Laureate remains confident in its growth and shareholder value enhancement strategies.

    Tip Ranks·
    US
    LAUR
    -1.02%
    Tip Ranks·
    US
    LAUR
    -1.02%

    Indivior Issues Correction on Exit Costs for Rest of World Business

    Indivior plc has amended its previous report on exiting several non-U.S. markets, including the U.K., Ireland, Sweden, Israel, Finland, and Italy. The updated filing includes revised estimates of costs and expenses related to this exit, particularly additional costs from discontinuing sales and marketing of OPVEE. It also reflects the current financial impact of these actions.

    Reuters·
    UK
    INDV
    0.00%
    US
    INDV
    +2.21%
    Reuters·
    UK
    INDV
    0.00%
    US
    INDV
    +2.21%